ERB-196
![]() |
|
Clinical data | |
---|---|
Synonyms | WAY-202196 |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H10FNO2 |
Molar mass | 279.27 g/mol |
3D model (JSmol) | |
|
|
|
ERB-196, also known as WAY-202196, is a synthetic, nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.[1][2][3][4][5][6] It possesses 78-fold selectivity for the ERβ over the ERα.[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.[2][7]
See also[edit]
References[edit]
- ^ a b R. E. Hubbard (2006). Structure-based Drug Discovery: An Overview. Royal Society of Chemistry. pp. 241–. ISBN 978-0-85404-351-4.
- ^ a b https://adisinsight.springer.com/drugs/800021229[permanent dead link]
- ^ Estrogens—Advances in Research and Application: 2013 Edition: ScholarlyBrief. ScholarlyEditions. 21 June 2013. pp. 52–. ISBN 978-1-4816-8771-3.
- ^ Eckhard Ottow; Hilmar Weinmann (8 September 2008). Nuclear Receptors as Drug Targets. John Wiley & Sons. pp. 66–. ISBN 978-3-527-62330-3.
- ^ Mewshaw RE, Edsall RJ, Yang C, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005). "ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity". J. Med. Chem. 48 (12): 3953–79. PMID 15943471. doi:10.1021/jm058173s.
- ^ Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC, Harris HA (2006). "WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock". Crit. Care Med. 34 (8): 2188–93. PMID 16755255. doi:10.1097/01.CCM.0000227173.13497.56.
- ^ Jean-Louis Vincent (8 December 2007). Yearbook of Intensive Care and Emergency Medicine 2007. Springer Science & Business Media. pp. 891–. ISBN 978-3-540-49433-1.
External links[edit]
![]() |
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |